Literature DB >> 26922429

Epigallocatechin-3-gallate inhibits transforming-growth-factor-β1-induced collagen synthesis by suppressing early growth response-1 in human buccal mucosal fibroblasts.

Yu-Ping Hsieh1, Hsin-Ming Chen2, Hung-Ying Lin3, Hsiang Yang3, Jenny Zwei-Chieng Chang4.   

Abstract

BACKGROUND/
PURPOSE: Transforming growth factor (TGF)-β is a key regulator in the pathogenesis of oral submucous fibrosis (OSF). Early growth response (Egr)-1 is essential for fibrotic responses to TGF-β. Because TGF-β signaling is cell-type- and context-dependent, we investigated the signaling involved in TGF-β-induced Egr-1 in primary human buccal mucosal fibroblasts (BMFs).
METHODS: TGF-β-induced Egr-1 and its signaling were assessed by western blotting in BMFs. Egr-1 small interfering RNA was used to define the role of Egr-1 on TGF-β-induced mRNAs of the α1- and α2-chains of type I collagen (COL1A1 and COL1A2) and acid-soluble collagen production (via Sircol collagen assay). The effects of epigallocatechin-3-gallate (EGCG) on TGF-β-induced Egr-1 protein and acid-soluble collagen were also evaluated.
RESULTS: TGF-β1 stimulated Egr-1 production in BMFs. Pretreatment with PD98059, SP600125, SB431542, and SIS3, but not SB203580, significantly reduced TGF-β1-induced Egr-1 protein expression. Genetic targeting of Egr-1 completely inhibited TGF-β1-induced type I collagen mRNAs and collagen protein expression. EGCG fully inhibited TGF-β1-induced Egr-1 and TGF-β1-stimulated production of acid-soluble collagens.
CONCLUSION: We conclude that activin receptor-like kinase (ALK)5, Smad3, extracellular signal-regulated kinase, and c-Jun N-terminal kinase are involved in the TGF-β1-induced Egr-1 protein production in BMFs. Egr-1 mediates TGF-β1-induced COL1A1 and COL1A2 mRNA expression and acid-soluble collagen production in BMFs. EGCG can block TGF-β1-induced collagen production by attenuating Egr-1 expression in BMFs. Egr-1 is a key mediator in TGF-β1-induced pathogenesis of OSF. EGCG may be useful in the prevention or treatment of OSF.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  early growth response-1; epigallocatechin-3-gallate; fibroblast; oral submucous fibrosis; transforming growth factor β

Mesh:

Substances:

Year:  2016        PMID: 26922429     DOI: 10.1016/j.jfma.2016.01.014

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  4 in total

Review 1.  A Comprehensive Analysis of the Role of Oxidative Stress in the Pathogenesis and Chemoprevention of Oral Submucous Fibrosis.

Authors:  Luciano Saso; Ahmad Reza; Emily Ng; Kimtrang Nguyen; Sheng Lin; Pangzhen Zhang; Paolo Junior Fantozzi; Guliz Armagan; Umberto Romeo; Nicola Cirillo
Journal:  Antioxidants (Basel)       Date:  2022-04-28

2.  Epigallocatechingallate attenuates myocardial injury in a mouse model of heart failure through TGF‑β1/Smad3 signaling pathway.

Authors:  Keyan Chen; Wei Chen; Shi Li Liu; Tian Shi Wu; Kai Feng Yu; Jing Qi; Yijun Wang; Hui Yao; Xiao Yang Huang; Ying Han; Ping Hou
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

3.  Bioflavonoid Galangin Suppresses Hypertrophic Scar Formation by the TGF-β/Smad Signaling Pathway.

Authors:  Zha Ru; Ying Hu; Shenghua Huang; Li Bai; Kun Zhang; Yue Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-04       Impact factor: 2.629

4.  Glucocorticoid counteracts cellular mechanoresponses by LINC01569-dependent glucocorticoid receptor-mediated mRNA decay.

Authors:  Huayu Zhu; Jun Li; Yize Li; Zhao Zheng; Hao Guan; Hongtao Wang; Ke Tao; Jiaqi Liu; Yunchuan Wang; Wanfu Zhang; Chao Li; Jie Li; Lintao Jia; Wendong Bai; Dahai Hu
Journal:  Sci Adv       Date:  2021-02-24       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.